The company “nearmedic” is preparing to release the pharmaceutical substance of the new anti-TB drug magazinea. The drug developed by GK “nearmedic” and the Swiss École Polytechnique Fédérale de Lausanne (EPFL) jointly with the international Fund Innovative medicines for tuberculosis (Im4TB).
In the near future the production site full cycle of the ASF magazinea (PBTZ 169) will be fully ready for the launch of a new production site research and production complex of OOO “nearmedic Pharma” in Obninsk.
Experimental magazine was a series of studies in Russia and the EU, which has been proven the safety and efficacy of its use in the treatment of tuberculosis with multiple and extensively drug-resistant. The research was conducted in 2014. At the moment, completing a full cycle of preclinical studies a series of clinical trials phase I in healthy volunteers and clinical phase II study investigating the efficacy and safety of the drug magazine when used in patients with newly diagnosed tuberculosis of respiratory organs.